D.M. Gaughan, M.D. Hughes, J.M. Oleske, K. Malee, S. Nachman, for the PACTG 219C Team.  Psychiatric hospitalizations among children and youths with human immunodeficiency virus infection. Pediatrics 2004;113(6):e544-e551.

J. Hitti, L.M. Frenkel, A.M. Stek, S.A. Nachman, D. Baker, A. Gonzalez-Garcia, A. Provisor, E.M. Thorpe, M.E. Paul, M. Foca, J. Gandia, S. Huang, L.J. Wei, L.M. Stevens, D.H. Watts, J. McNamara, for the PACTG 1022 Study Team.  Maternal toxicity with continuous nevirapine in pregnancy: Results from PACTG 1022. J Acquir Immune Defic Syndr 2004;36(3):772-776.

C.V. Fletcher, R. Yogev, S.A. Nachman, A. Wiznia, S. Pelton, K. McIntosh, and K. Stanley.  Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection. Pharmacotherapy 2004;24(4):453-9.

R.J. Jeremy, S. Kim, M. Nozyce, S. Nachman, K. McIntosh, S.I. Pelton, R. Yogev, A. Wiznia, G.M. Johnson, P. Krogstad, and K. Stanley for the Pediatric AIDS Clinical Trials Group (PACTG) 338 & 377 Study Teams.  Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children. Pediatrics 2005;115(2):380-387.

S. Nachman,  P. Gona, W. Dankner, A. Weinberg, R. Yogev, A. Gershon, M. Rathore, J. S. Read, S. Huang, C. Elgie, K. Hudgens, and W. Hughes.  The Rate of Serious Bacterial Infections Among HIV-Infected Children with Immune Reconstitution Who Have Discontinued Opportunistic Infection Prophylaxis. Pediatrics 2005;115:488-494.

S.A. Nachman, J.C. Lindsey, J. Moye, K.E. Stanley, G.M. Johnson, P.A. Krogstad, and A.A. Wiznia for the PACTG 377 Study Team. Growth of human immunodeficiency virus-infected children receiving highly active antiretroviral therapy. J Pediatr Infect Dis 2005;24(4):352-357.

S.I. Pelton, K. Stanley, R. Yogev, C.V. Fletcher, K. McIntosh, A. Wiznia, and S. Nachman for the PACTG 338 Study Team.  Switch from ritonavir to indinavir combination therapy for HIV-infected children. Clin Infect Dis 2005;40:1181-7.

H.M. Rosenblatt, K.E. Stanley, L.Y.Song, G.M. Johnson, A.A. Wiznia, S.A. Nachman, P.A. Krogstad and the PACTG 377 Study Team. Immunologic response to combination therapy in children with clinically stable HIV infection. J Infect Dis 2005;192:445-455.

S.K. Gupta, J.A. Eustace, J.A. Winston, I.I. Boydstun, T.S. Ahuja, R.A. Rodriguez, K.T. Tashima, M. Roland, N. Franceschini, F.J. Palella, Jr., J.L. Lennox, P.E. Klotman, S.A. Nachman, S.D. Hall, L.A. Szczech. Guidelines for the management of chronic kidney disease in HIV-infected patients: Recommendations of the HIV Medical Association of the Infectious Diseases Society of America. Clin Infect Dis 2005;40(11):1559-85.

J.Y. Ang, S. Ray-Mazumder, S.A. Nachman, C. Rongkavilt, B.I. Asmar and C.L. Ren. Use of complementary and alternative medicine by parents of pediatric HIV, pediatric asthma and well child patients. South Med J 2005; 98(9):869-75.

L.J. Grando, D.C. Machado, S. Spitzer, S. Nachman, F. Ferguson, B. Berentsen, L.S. Yurgel. Viral coinfection in the oral cavity of HIV-infected children: relation among HIV viral load, CD4+ T lymphocyte count and detection of EBV, CMV and HSV.  Pesquisa Odontologica Brasileira (Brazilian Oral Research) 2005;19(3):228-34.

H.M. Rosenblatt, L.Y. Song, S.A. Nachman, K.E. Stanley, P.A. Krogstad, G.M. Johnson, A.A. Wiznia and the PACTG 377 Study Team. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immunol 2005;116(3):698-703.

J.R. King, S. Nachman, R. Yogev, J. Hodge, G. Aldrovandi, M.D. Hughes, J. Chen, A. Wiznia, B. Damle, E.P. Acosta. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in HIV-infected children – PACTG 403. Pediatr Infect Dis J 2005; 24(10):880-885.

H.M. Rosenblatt, L.Y. Song, S.A. Nachman, K.E. Stanley, P.A. Krogstad, G.M. Johnson, and A.A. Wiznia. Tetanus immunity after diphtheria, tetanus toxoids, and acellular pertussis vaccination in children with clinically stable HIV infection. J Allergy Clin Immun 2005; 116(3):698-703.

L. Gabis, A. Belman, W. Huang, M. Milazzo, and S. Nachman. Clinical and imaging study of HIV-1 infected youth on HAART therapy – A pilot study using MR spectroscopy. Accepted J Child Neurol, July 2005.

P Gona, R.B. Van Dyke, P.L. Williams, W.M. Dankner, M.M. Chernoff, S.A. Nachman, G.R. Seage III.  Incidence of opportunistic and other infections in HIV-infected children in the HAART-era.  Accepted Archives of Pediatrics and Adolescent Medicine Dec 2005.

M.L. Nozyce, S.S. Lee, A. Wiznia, S. Nachman, L. Mofenson, E. Smith, R. Yogev, K. McIntosh, K. Stanley, S. Pelton. A behavioral and cognitive profile of clinically stable HIV infected children receiving antiretroviral therapy. Pediatrics 2006 Mar;117(3):763-70.

Weinberg, P. Gona, S.A. Nachman, P. Defechereux, R. Yogev, W. Hughes, D. Wara, C. Elgie, M. Cooper, W. Dankner and the PACTG 1008 Team. Antibody responses to hepatitis A vaccine among HIV-infected children with evidence of immunologic reconstitution on antiretroviral therapy. J Infect Dis Jan 2006;193(2):302-11.

Englund J, Raskino C, Vavro C, Palumbo P, Ross L, McKinney R, Nikolic-Djokic D, Colgrove R, Baker C. Mutations linked to drug resistance, HIV biological phenotype, and their association with disease progression in HIV-infected children receiving nucleoside reverse transcriptase inhibitors. Pediatr Infect Dis J. 2004;23(1):15-22.

McCloskey, TW, Haridas, V, Pontrelli, L, and Pahwa, S.  Response to Superantigen Stimulation in Peripheral Blood Mononuclear Cells from Children Perinatally Infected with Human Immunodeficiency Virus and Receiving Highly Active Antiretroviral Therapy.  Clin.Diagn.Lab.Immunol. 2004, 11 (5): 957-962.